Drug Database
AZ

azithromycin (Azimac)

✓ Approved

Beijing Holley-Cotec Pharma · Small Molecule · Small Molecule

What is azithromycin?

azithromycin is a small molecule developed by Beijing Holley-Cotec Pharma. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesAzimac
CompanyBeijing Holley-Cotec Pharma
Drug ClassSmall Molecule
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Beijing Holley-Cotec Pharma

Therapeutic Indications

azithromycin is developed for 8 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Infections and infestationsLower respiratory tract infection✓ Approved
Infections and infestationsOtitis media✓ Approved
Infections and infestationsSinusitis✓ Approved
Infections and infestationsTonsillitis✓ Approved
Infections and infestationsUrinary tract infection✓ Approved

+3 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedJournal of tropical pediatrics2026-05-23

Beyond the Lungs: Rising Pediatric Mycoplasma pneumoniae Infections with Extrapulmonary Manifestations in the Post-COVID-19 Pandemic Era.

Kuruc Aylin Irmak AI, Aykac Kubra K, Cengiz Ali Bulent AB, Ozsurekci Yasemin Y

Following the relaxation of COVID‑19 mitigation strategies, Mycoplasma pneumoniae (MP) infections have resurged worldwide. Although respiratory involvement predominates, extrapulmonary manifestations in children are increasingly recognized. We aim to report a recent rise in pediatric MP infections with notable extrapulmonary features, including rash, mucositis, acute myocarditis, and other parainfectious eruptions. We describe 6 pediatric cases with extrapulmonary MP manifestations admitted to our center from March 2025 to October 2025. The diagnosis was confirmed through serology or PCR testing. We reviewed the clinical features, laboratory results, and treatment outcomes. Five patients exhibited generalized targetoid rashes, often accompanied by fever, conjunctival hyperemia, or mucosal changes. The median age 14 years (min: 13 months -max: 17.5 years), and 3 patients were female. Several were initially misdiagnosed as meningococcemia, Kawasaki disease, or MIS‑C. One adolescent developed MP‑associated acute myocarditis, with hypotension, elevated cardiac markers, and mild cardiomegaly. Another patient presented with reactive infectious mucocutaneous eruption (RIME) limited to oral lesions. All patients received macrolide therapy (clarithromycin or azithromycin), with rapid clinical improvement, resolution of lesions, normalization of cardiac markers, and no major adverse effects. MP infection in children may present with dermatologic, mucocutaneous, or cardiac involvement even in the absence of respiratory symptoms. Clinical awareness beyond respiratory findings is crucial to avoid misdiagnosis and inappropriate treatment. Broader diagnostic and surveillance approaches are needed to improve recognition, especially in the context of evolving post‑pandemic host and pathogen dynamics.

PMID 42173085
Read full article →
PubMedParasitology international2026-05-23

Randomized clinical trial evaluating triazolopyridazine SLU-2633 as a treatment for gastric cryptosporidiosis in eastern indigo snakes (Drymarchon couperi).

Bogan James E JE, Huston Christopher D CD, Meyers Marvin J MJ, Logel Rhiannon R et al.

Gastric cryptosporidiosis caused by Cryptosporidium serpentis has negatively impacted the conservation efforts for the imperiled eastern indigo snake (EIS, Drymarchon couperi). Multiple treatments, including paromomycin, nitazoxanide-azithromycin-rifabutin, clofazimine, curcumin, hydrogen peroxide gavage, and triazolopyridazine MMV665917 have proved ineffective in eliminating the parasite. In a structure-activity relationship study, a 10-fold more potent analog of MMV665917 (SLU-2633) was discovered. Additionally, greater potency of SLU-2633 improved the therapeutic index of this compound. When SLU-2633 was evaluated in mice, oral administration of 50 mg/kg twice daily for four days caused a 99% reduction in parasite burden; and the mice were Cryptosporidium-free ten days post-treatment. With these promising results, SLU-2633 was selected as a potential treatment of gastric cryptosporidiosis in EIS. Ten EISs naturally infected with C. serpentis were randomly divided into two groups of five. Group A received 50 mg/kg SLU-2633 once daily for four days, then twice weekly for six weeks, and Group B received the diluent once daily for four days, then twice weekly for six weeks. Group A had significantly lower levels of C. serpentis DNA three weeks after the initial dose (P = 0.047) through one month after cessation of drug administration (P = 0.018). However, two months after cessation of drug administration, there was no longer a difference between the two groups (P = 0.27). At this dosing regimen, SLU-2633 reduced the overall burden of C. serpentis DNA by 88% suggesting that SLU-2633 may be effective in eliminating C. serpentis infection in EIS with an optimized dosing regimen or formulation.

PMID 42173191
Read full article →
PubMedMedicine2026-05-23

Clinical characteristics and predictors of Mycoplasma pneumoniae pneumonia coinfection with Bordetella pertussis in children.

Lai Chongyuan C, Peng Shuping S, Wu Xianfei X

This study aimed to investigate the clinical characteristics of Mycoplasma pneumoniae (MP) pneumonia coinfection with Bordetella pertussis (BP) in children and to determine the predictors of BP coinfection. Children with MP pneumonia (MPP) admitted to The First People's Hospital of NanKang District between January 2024 and January 2025 were screened. Patients with BP coinfection were assigned to the study group, while those with mono-infection of MP were assigned to the control group at a 1:1 ratio, matched by age and admission time. Clinical data were compared between the 2 groups. Multivariate logistic regression analysis was performed to evaluate the association between BP coinfection, severe pneumonia, and azithromycin (AZM) treatment failure. Receiver operating characteristic (ROC) curve analysis was used to identify the potential predictive factors for BP coinfection. A total of 1475 hospitalized children with MPP were screened. Forty children were enrolled in the study and 40 in the control group. Children in the study group had a higher incidence of fever and spasmodic cough as well as a longer duration of fever and cough. They also exhibited an elevated white blood cell (WBC) count and lymphocyte (LYM) percentage, higher rates of severe pneumonia, oxygen therapy, bronchoalveolar lavage, methylprednisolone use, longer hospital stays, and higher hospitalization costs. Coinfection with BP was associated with severe MP pneumonia (P = .017) and treatment failure (P = .038). The area under the ROC curve (AUC) values for WBC count, LYM percentage, fever duration, and cough duration were 0.644 (95% CI: 0.521-0.768, P = .028), 0.641 (95% CI: 0.521-0.760, P = .032), 0.638 (95% CI: 0.516-0.761, P = .036), and 0.698 (95% CI: 0.576-0.820, P = .003), respectively. BP coinfection in children with hospitalized MPP is associated with an increased risk of severe pneumonia and treatment failure, which may complicate clinical management and increase disease burden. WBC count, LYM percentage, fever duration, and cough duration could serve as predictive factors for BP coinfection.

PMID 42175396
Read full article →
PubMedMedicine2026-05-23

Mycobacterium avium complex pulmonary disease in rheumatoid arthritis-associated interstitial lung disease under non-biologic immunomodulatory therapy: A case report.

Tang Ruixia R, Wang Run R, Han Yongmei Y

Rheumatoid arthritis (RA) is a well-recognized risk factor for nontuberculous mycobacterial infections, especially among patients receiving glucocorticoids or biological disease-modifying antirheumatic drugs. However, cases of Mycobacterium avium complex (MAC) pulmonary disease in RA patients without such immunosuppressive therapies are rarely reported, which challenges the conventional risk stratification. A 78-year-old male with a 3-year history of RA and interstitial lung disease (ILD) presented with progressive dyspnea and chest tightness. He had no fever, joint swelling, or typical infection flares. Before admission, he was treated with Tripterygium Glycosides and Iguratimod (non-biologic, non-glucocorticoid agents). The patient had chest tightness and weight loss. Chest high-resolution computed tomography showed asymmetric progression of ILD, along with tree-in-bud signs, centrilobular nodules, and suspicious fibrocavities. Bronchoscopy revealed necrotizing granulomatous inflammation, and quantitative metagenomic sequencing of bronchoalveolar lavage fluid confirmed MAC (no drug-resistant genes detected). The patient was put on a 4-drug anti-MAC regimen (rifampicin, azithromycin, ethambutol, amikacin). However, he was lost to follow-up after being transferred to a tuberculosis specialist hospital. He eventually died of unknown causes, and there were prior reports of his nonadherence to treatment. For RA patients with ILD who show asymmetric imaging progression or discordant inflammatory markers, it is crucial to actively screen for atypical pathogens like MAC, even in the absence of glucocorticoid or biologic exposure. This case highlights the necessity of expanding nontuberculous mycobacterial infection risk assessment beyond traditional immunosuppressive therapies in RA-ILD patients. For patients with autoimmune disease-associated interstitial pneumonia, particularly those with progressive interstitial lung disease (ILD) despite stable autoimmune serology, proactive screening for atypical pathogens such as nontuberculous mycobacteria is critical. When imaging shows asymmetric lesions, tree-in-bud opacities, centrilobular nodules, or fibrocavitary changes, clinicians should prioritize comprehensive etiological evaluation - including bronchoscopy and histopathology - to avoid misdiagnosing these opportunistic infections.

PMID 42175403
Read full article →
PubMedMolecular biology reports2026-05-22

Effects of quercetin, baicalein, azithromycin, and their combination on biofilm formation, virulence factors and gene expression associated with Pseudomonas aeruginosa quorum sensing.

Parra Rodríguez Valentina V, Gómez Vanessa V, Pabón Ludy Cristina LC, Hernández-Rodríguez Patricia P

Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen commonly associated with acute and chronic hospital-acquired infections. Its ability to form biofilms, regulated in part by quorum sensing, contributes to its persistence and resistance. Classified as a critical priority pathogen by the World Health Organization, there is an urgent need for new therapeutic strategies. In this study, we evaluated the effects of quercetin, baicalein and azithromycin, alone and in combination, on biofilm formation, virulence factor production, and quorum sensing gene expression in P. aeruginosa PAO1. The minimum inhibitory concentration of each compound was measured. The effect of each compound and their combinations on biofilm formation, elastases, pyocyanin and rhamnolipids were evaluated by spectrophotometric assays, and on lasR and mvfR gene expression by RT-qPCR. The minimum inhibitory concentrations of quercetin, baicalein and azithromycin were > 250, 62, and 16 µg/mL, respectively. The individual compound with the lowest percentage of biofilm formation was quercetin, followed by azithromycin and baicalein with 33%, 48%, and 51%, and the best combination was azithromycin-baicalein with 35%. Azithromycin and the mentioned combination showed the lowest production of elastases, pyocyanin and rhamnolipids (39% and 34%; 8% and 13%; 19% and 16%, respectively) and resulted in lasR and mvfR gene expression levels of 32% and 34%. The combination of azithromycin-baicalein showed inhibitory effects on biofilm formation, virulence factors and gene expression of lasR and mvfR. These findings highlight the potential of combining natural products with antibiotics as a promising strategy to attenuate virulence and disrupt quorum sensing-regulated behaviors in P. aeruginosa.

PMID 42171829
Read full article →
PubMedThorax2026-05-21

Making sense of azithromycin resistance patterns: what have we learnt and what should we do?

Carroll Will W, Chapman James J, Gilchrist Francis J FJ

PMID 42161596
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about azithromycin